Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration (nAMD) Clinical Trial

Official title:
A Real-world, Prospective, Multi-center, Open-label, Phase IV Clinical Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Status Completed

Clinical Trial Summary

The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated with brolucizumab. This study was conducted as part of the post-marketing regulatory commitment to the Indian Health authority.

Clinical Trial Description

The study was a prospective, multi-center, open-label, interventional phase IV clinical study. The study treatment, i.e., brolucizumab was prescribed in terms of the marketing authorization; the assignment of the patient to the therapy was decided within the current practice and the medical indication. It was clearly separated from the decision to include the patient in the study. All patients with Neovascular Age-related Macular Degeneration (nAMD) who were planned to be treated with brolucizumab and had provided informed consent were enrolled in the study. A total of 12 sites in India were evaluated for the study conduct. This is to note that site #03 was not selected, and site #07 was not initiated, and patients were enrolled in the study only from 10 sites. The treatment period for each patient was 56 weeks after the start of brolucizumab treatment. Study visits were scheduled at Week 4, Week 8, Week 16, and thereafter at intervals of 8 weeks or 12 weeks after disease activity assessment at Week 16. If the investigators required more frequent follow-up visits, it was done according to their discretion and clinical judgment. Any patient who suffered from IOI during the study period was not re-challenged with brolucizumab. The study population consisted of adult male and female outpatients aged 50 years and above, diagnosed with nAMD for whom the treating the physician (Investigator) had prescribed treatment with brolucizumab 6 mg injection in adherence with the local Summary of Product Characteristics (SmPC) or Prescribing Information (PI). ;

Study Design

Related Conditions & MeSH terms

Macular Degeneration
Neovascular Age-related Macular Degeneration (nAMD)
Wet Macular Degeneration

Clinical Trial Details

NCT number	NCT05269966
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 4
Start date	March 9, 2022
Completion date	August 29, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04543331` - Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Recruiting	`NCT05904691` - Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration	Phase 1
Completed	`NCT05282004` - Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit	Phase 3
Active, not recruiting	`NCT04764656` - Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
Completed	`NCT05161806` - Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe	Phase 3
Recruiting	`NCT04657289` - A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)	Phase 3
Recruiting	`NCT06116890` - Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	Phase 2
Recruiting	`NCT06075147` - The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
Terminated	`NCT04746963` - Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration	Phase 1/Phase 2
Recruiting	`NCT05769153` - Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)	Phase 1/Phase 2
Enrolling by invitation	`NCT05210803` - Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Recruiting	`NCT04514653` - RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)	Phase 2
Not yet recruiting	`NCT06398080` - An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
Active, not recruiting	`NCT05989126` - Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.